Abstract 4706: Evaluating the efficacy of RAS(ON) inhibitor RMC-6236 combined with chemotherapy and other targeted therapies in 3D models involving patients with KRAS-mutated pancreatic cancer
Taylor Bargenquast(HonorHealth), Sunil Sharma(HonorHealth), Mohan R. Kaadige(Translational Genomics Research Institute), Janith Don(Translational Genomics Research Institute), Guangfa Zhang(Translational Genomics Research Institute), Tithi Ghosh(Translational Genomics Research Institute), Trason Thode(Translational Genomics Research Institute), C. John Wesley(Translational Genomics Research Institute), Serina Ng(Translational Genomics Research Institute), Raffaella Soldi(Banner Health), Erkut Borazanci(HonorHealth), Alexis Weston(Translational Genomics Research Institute), Nicholas J. Schork(Scripps Research Institute), Sara A. Byron(Translational Genomics Research Institute)
Cited by 1
Related Papers
Genetic Dissection of Complex Traits
|Science|1994|3.5k
Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites
|Nature Genetics|2017|485
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer
|JAMA Oncology|2019|289
Selective Loss of Sphingosine 1-Phosphate Signaling with No Obvious Phenotypic Abnormality in Mice Lacking Its G Protein-coupled Receptor, LPB3/EDG-3
|Journal of Biological Chemistry|2001|272
Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci
|The American Journal of Human Genetics|2012|269